Hepatitis B: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 4
• PD-L1 2
• TP53 0
• STAT3 0
• STING 0
• CD19 0
• TNF 0
• AMPK 0
• JAK 0
• mTOR 0
• CD20 0
• EGFR 0
• ERK 0
• GPC3 0
• HIF-1 0
• IL-1 0
• IL-6 0
• PI3K 0
• PPAR 0
• TFEB 0
• ABL1 0
• AKT 0
• BCL-2 0
• CTLA-4 0
• G6PD 0
• HMGB1 0
• HSP90 0
• IL-17 0
• MYC 0
• NRF2 0
• PARP 0
• VEGF 0
• ALK 0
• AQP4 0
• ARID1A 0
• CCR5 0
• CD33 0
• CD38 0
• CD40 0
• CTNNB1 0
• FAK 0
• FGFR 0
• HDAC 0
• IL-23 0
• IL-4 0
• KRAS 0
• LAG-3 0
• MAPK 0
• METTL3 0
• MMP-9 0
• NLRP3 0
• NOTCH1 0
• PKM2 0
• PNPLA3 0
• PRMT5 0
• PSMA 0
• PTEN 0
• SGLT2 0
• TERT 0
• TIM-3 0

24 of 629 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding Immune Aging in Chronic Hepatitis B (DECAGE)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €209,483· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Implementation of an Integrated Digital Health System for Infectious Diseases in Maternal and Child Health In East Africa (LINDA-FAMILIA)

  University College Cork - National University of Ireland, Cork· Cork, Ireland· EU contribution €4,998,563· until Jul 2029· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Innovative Point of Care for combined screening of Infectious diseases: application to Prevention of Mother to Child Transmission (MAGFA)

  Magia Diagnostics· Echirolles, France· EU contribution €5,078,816· until Dec 2027· 4 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Acquired adaptive immune cell dysfunction and restoration in chronic hepatitis B (EUCLIDEAN)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €2,500,000· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-RIA

  Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D (D-SOLVE)

  Medizinische Hochschule Hannover· Hannover, Germany· EU contribution €6,754,010· until Sept 2027· 5 countries

  The disease is named only in the funder's project summary, not in the title.

5 of 7 running projects, newest first. Listed amounts together: €32.5m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Optimal Timing of Hepatitis B Vaccination After Transplants

  NCT06888479· Institute of Hematology & Blood Diseases Hospital, China· Updated 12 Nov 2026

  “Insufficient execution and compliance”Registry text, quoted unchanged. Source

• Terminated

  Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C

  NCT06082336· MagIA Diagnostics· Updated 11 Sept 2026

  “Liquidation of MagIA Diagnostics”Registry text, quoted unchanged. Source

• Withdrawn

  PREHEVBRIO Pregnancy Outcomes Registry

  NCT06097312· VBI Vaccines Inc.· Updated 11 May 2026

  “Company out of business”Registry text, quoted unchanged. Source

• Terminated

  HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers

  NCT05272735· Rockefeller University· Updated 16 Apr 2026

  “The yield of cells recovered from the lymph node fine needle aspirations was low limiting the ability to perform the planned immunologic assessments following HBV vaccination.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

  NCT05763576· Hoffmann-La Roche· Updated 22 Jan 2026

  “The Sponsor decided to discontinue the development of RO7565020 and as a result the BP44118 study was terminated.”Registry text, quoted unchanged. Source

• Terminated

  HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)

  NCT04684914· Altimmune, Inc.· Updated 8 Dec 2025

  “Did not meet endpoints”Registry text, quoted unchanged. Source

• Terminated

  An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

  NCT03692897· Target PharmaSolutions, Inc.· Updated 17 Sept 2025

  “Study Closure”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

  NCT06990776· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Updated 3 Aug 2025

  “Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment

  NCT05550519· Janssen Pharmaceutica N.V., Belgium· Updated 25 Jun 2025

  “Sponsor Decision after re-evaluation of strategy in the context of recruitment timelines projection”Registry text, quoted unchanged. Source

• Withdrawn

  Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)

  NCT05482282· PT Bio Farma· Updated 5 Jun 2025

  “The products will be replace with others.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Optimal Timing of Hepatitis B Vaccination After Transplants

  NCT06888479· Institute of Hematology & Blood Diseases Hospital, China· Source

• Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)

  NCT07855172· Serum Institute of India Pvt. Ltd.· Source

• A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

  NCT06537414· GlaxoSmithKline· Source

• Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

  NCT06497504· GlaxoSmithKline· Source

• Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

  NCT04954859· GlaxoSmithKline· Source

• B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants

  NCT07908459· GlaxoSmithKline· Source

• Understanding Poor Vaccine Responses to Hepatitis B Vaccination

  NCT04674462· NYU Langone Health· Source

• Essentiale® liquid once-daily Phase III study

  2025-521678-32-00· Opella Healthcare Group S.A.S.· Source

• Blood Collection Biorepository for Liver Disease Research

  NCT03025074· State University of New York at Buffalo· Source

• Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

  NCT05832229· National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 12
• Organoids 3
• Mendelian Randomization Analysis 7
• CRISPR-Cas Systems 23
• Gene Expression Profiling 26
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 2
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 10
• Mass Spectrometry 2
• Flow Cytometry 3
• Immunohistochemistry 4
• Liquid Biopsy 2
• Xenograft Model Antitumor Assays 2
• Magnetic Resonance Imaging 22
• Machine Learning 38
• Deep Learning 6
• Cohort Studies 63
• Genome-Wide Association Study 12

• Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway.

  PLoS One, Jun 2026

• Targeting circGDI2 disrupt HNRNPC-mediated mPORCN stabilization and enhance LGK-974 anti-tumor therapy in hepatocellular carcinoma.

  Mol Cancer, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.